AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03787979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study NCT02648828 — intervention group
Intervention type: OTHER
Intervention: Clinical deterioration
Description: Patients at risk of clinical deterioration
Study NCT02408432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02408432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02408432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Undergo mesenchymal stem cell infusion
Study NCT02408432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Undergo mesenchymal stem cell infusion
Study NCT02408432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell Transplantation
Description: Undergo mesenchymal stem cell infusion
Study NCT02408432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cell Transplantation
Description: Undergo mesenchymal stem cell infusion
Study NCT00637143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral
Study NCT00637143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Oral
Study NCT01293578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice Cards
Description: Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
Study NCT04662827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmithylethanolamid
Description: PEA 3x/d
Study NCT04662827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palmithylethanolamid
Description: PEA 3x/d
Study NCT04662827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo 3x/d
Study NCT04662827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 3x/d
Study NCT02853799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients
Description: 1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated.
Study NCT02853799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Osmolite 1.2 cal/ml Enteral Feeds
Description: Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
Study NCT02744742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.
Study NCT02744742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT02744742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT02744742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT02744742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT02744742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study NCT03848156 — intervention group
Intervention type: OTHER
Intervention: biopsy
Description: Biopsy of nasal polyp for RNA sequencing
Study NCT02761837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVR call/text
Description: For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
Study NCT02761837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email
Description: Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
Study NCT02029690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study NCT00813176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Lumen Endotracheal Tube
Study NCT00813176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arndt Bronchial Blocker
Study NCT04227054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPEDE-FX Embolization Plug
Description: Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
Study NCT00895011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose 30 minutes prior to initiation of sexual activity
Study NCT00895011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: One dose 30 minutes prior to initiation of sexual activity
Study NCT03656471 — intervention group
Intervention type: DEVICE
Intervention: clear aligners or fixed appliances
Description: Patients choose clear aligners or fixed appliances to treat their malocclusions
Study NCT00052442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Study NCT00923364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX, Cytoxan)
Description: 14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
Study NCT00923364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine(Fludara,Berlex Laboratories)
Description: 40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
Study NCT00923364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
Study NCT00923364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell (HSC)
Description: stem cell transplant
Study NCT00923364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equine Anti-Thymocyte Globulin
Description: 30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
Study NCT01752036 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Post-operative, Stereotactic Body Radiation Therapy (SBRT)
Description: All participants received SBRT at 600 cGy x 5 fractions
Study NCT02816164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Subcutaneous injections
Study NCT00270894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
Study NCT00270894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
Study NCT00270894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
Study NCT00270894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
Study NCT03933943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237
Description: Administered SC
Study NCT03933943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03285815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Study NCT01479218 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Occlutech PDA occluder
Description: Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
Study NCT01465139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days
Study NCT03922802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training
Description: Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.
Study NCT03922802 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training
Description: Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
Study NCT03922802 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training
Description: Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
Study NCT03661684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg po q day of Prednisone for 3 days
Study NCT02368470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemifloxacin-based triple therapy
Description: Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
Study NCT02368470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard triple therapy
Description: Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
Study NCT02505048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rucaparib
Description: 600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
Study NCT02737046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Alfa-2b
Description: OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
Study NCT02737046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-Alfa-2b
Description: OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
Study NCT03270462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Envarsus XR
Description: Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
Study NCT03333616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
Study NCT03333616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
Study NCT00801164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frio Mouth Rinse Placebo
Description: Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
Study NCT00801164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frio Mouth Rinse
Description: Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
Study NCT04627467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 250mg tablet (150mg base chloroquine)
Study NCT01675765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy plus chemotherapy
Description: live attenuated double deleted Lm
Study NCT01675765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with cyclophosphamide plus chemotherapy
Description: live attenuated double deleted Lm
Study NCT00687063 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
Study NCT02608177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Receives 4 weeks of study drug linagliptin
Study NCT02608177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Receives 4 weeks of study drug glipizide
Study NCT03818841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula device
Description: Patients will be randomly allocated to this treatment
Study NCT03818841 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-rebreathing oxygen mask group
Description: Patients will be randomly allocated to this treatment
Study NCT02322983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control of Stress
Description: To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
Study NCT03126305 — intervention group
Intervention type: OTHER
Intervention: OC-Go
Description: OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
Study NCT01467791 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observe patients
Study NCT03756272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bupivacaine block
Description: stellate ganglion bupivacaine injection
Study NCT03756272 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ganglion block
Description: stellate ganglion sodium chloride injection
Study NCT00813215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on saturated fat.
Study NCT00813215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on saturated fat.
Study NCT00813215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on monounsaturated fat
Study NCT00813215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal challenge
Description: Meal challenge with a test meal rich on monounsaturated fat
Study NCT02139839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus capsules
Description: L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
Study NCT02139839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus capsules
Description: L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
Study NCT02139839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gelatin pill
Description: Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
Study NCT02139839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gelatin pill
Description: Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
Study NCT04175808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM)
Description: Oral solution
Study NCT04175808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution
Study NCT04175808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg moxifloxacin oral tablet
Study NCT01446094 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
Study NCT00871247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg Tablet, single dose
Description: A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
Study NCT00871247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proscar® 5 mg Tablet, single dose
Description: B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
Study NCT03309774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~* Questionnaire KIDSCREEN 52~* Visual Analogue Scale (EVA)~* Neuropathic Pain 4 (DN4)~* Pain of the child Gustave Roussy (DEGR)
Study NCT03309774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: holter electrocardiogram
Description: Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
Study NCT03309774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood pressure
Description: Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
Study NCT03309774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation sessions
Description: Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale.
Study NCT01191879 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood test
Study NCT01910311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01910311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Administered orally
Study NCT01566812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast feeding optimization
Description: Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
Study NCT01566812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care applied in the hospital
Study NCT01566812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care applied in the hospital
Study NCT01847131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxymetazoline
Description: 0.05% Oxymetazoline nasal sprays were commercially available.
Study NCT01847131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
Study NCT03957460 — intervention group
Intervention type: OTHER
Intervention: SpHb monitoring
Description: Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).